Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium
BACKGROUND: HIV-associated neurocognitive disorder (HAND) remains highly prevalent despite effective anti-retroviral therapy (ART). A number of adjunctive pharmacotherapies for HAND have been studied with disappointing results, but preliminary data suggest that lithium may provide clinical benefit....
Main Authors: | Decloedt, E, Freeman, C, Howells, F, Casson-Crook, M, Lesosky, M, Koutsilieri, E, Lovestone, S, Maartens, G, Joska, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Lippincott, Williams & Wilkins
2016
|
Similar Items
-
Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trial
by: Maia Lesosky, et al.
Published: (2017-06-01) -
Signatures of HIV-1 subtype B and C Tat proteins and their effects in the neuropathogenesis of HIV-associated neurocognitive impairments
by: Monray E. Williams, et al.
Published: (2020-03-01) -
Integrating HIV-Associated Neurocognitive Impairment Screening within Primary Healthcare Facilities: A Pilot Training Intervention
by: Adele Munsami, et al.
Published: (2022-01-01) -
An overview of neurocognitive impairment in older people living with HIV
by: Rachel QM Ng, et al.
Published: (2023-02-01) -
NEUROCOGNITIVE IMPAIRMENT IN HIV/AIDS: A CONCEPTUAL FRAMEWORK
by: Linlin Lindayani, et al.
Published: (2018-09-01)